Abdominal soft tissue sarcoma: a multicenter retrospective study

Nishimura, Junichi; Morii, Eiichi; Takahashi, Tsuyoshi; Souma, Yoshihito; Nakajima, Kiyokazu; Doki, Yuichiro; Nishida, Toshirou

doi:10.1007/s10147-010-0075-4

Cited by 13 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A treatment protocol has not been established because of a lack of prospective randomized clinical trials. After complete resection, the most common treatment approach is anthracycline-based adjuvant chemotherapy for patients with large tumor size and high-grade tumors (1,3,5). Radiotherapy is a less effective treatment in leiomyosarcoma of the gastrointestinal tract.…”

Section: Discussionmentioning

confidence: 99%

Primary mesenchymal tumors of the colon: A report of three cases

Yaren

Değirmencioğlu²,

Demirkan³

et al. 2014

Turk J Gastroenterol

View full text Add to dashboard Cite

Primary mesenchymal tumors of the colon are extremely rare tumors among soft tissue sarcomas. These tumors are more aggressive and have poorer prognosis than adenocarcinoma of the colon. Here, we presented 3 cases of primary mesenchymal tumors of the colon. Their histopathological diagnoses are leiomyosarcoma, pleomorphic liposarcoma, and desmoplastic small round cell tumor, respectively. The rarity of primary mesenchymal tumors of the colon makes it difficult to approach the treatment and predict the prognosis of these rare tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

Primary mesenchymal tumors of the colon: A report of three cases

Yaren

Değirmencioğlu²,

Demirkan³

et al. 2014

Turk J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…The 5‐year overall survival and recurrence free survival was 62% and 23% respectively for the whole cohort. The 3‐year recurrence free survival of low grade RPS was 42% compared with 29% for the high‐grade RPS . The Royal Marsden Group have recently published on their updated experience on 200 patients treated from 1990 with a median follow‐up period of 29 months.…”

Section: Discussionmentioning

confidence: 99%

Outcomes of preoperative radiotherapy and resection of retroperitoneal sarcoma

Alford

Choong

Chander

et al. 2012

ANZ Journal of Surgery

View full text Add to dashboard Cite

show abstract

“…24,26 A median OS of 33 to 49 months was reported among patients who underwent surgery alone, 31,38 and the recurrence-free survival rate dropped to only 23%. 32 Depending on resection status, the 5-year local recurrence-free survival (LRFS) rate varied between 55% and 62%. The postoperative mortality rate was 3%, and postoperative complications that required reintervention occurred in 24 patients (12%).…”

Section: Surgery Alonementioning

confidence: 99%

Radiotherapy and surgery—An indispensable duo in the treatment of retroperitoneal sarcoma

Voorde

Delrue

Eijkeren

et al. 2011

Cancer

View full text Add to dashboard Cite

The authors undertook a systematic review to designate the role that radiotherapy (RT) might play in the treatment of retroperitoneal sarcomas. Correlating with recent literature, the objective of this review was to evaluate whether there was enough evidence for the authors to develop an institutional treatment protocol concerning the use of RT in the treatment of retroperitoneal sarcoma. Furthermore, this was a call for surgeons to talk to radiation oncologists before performing surgery. The 2 objectives of this review were: 1) to determine the benefit of RT in terms of local control and/or survival in the treatment of retroperitoneal sarcomas and 2) to discover the optimal timing of RT in the treatment sequence. A computerized literature search was performed in the PubMed database, the Cochrane Library database, and reference lists; and journals also were searched by hand to identify all retrospective and prospective reports published since 1998 relating to RT treatment of adult retroperitoneal sarcoma. Mainly, analyses were sought that were based on a 5-year local control rate (LCR), 5-year disease-free survival, and 5-year overall survival (OS). If only 2 years follow-up were available, then the authors also noted this outcome. Toxicity data were collected and analyzed separately. The synthesis of the literature was based on 9 prospectively nonrandomized studies and 10 retrospective studies that, together, reviewed a total of 1426 patients. The 5-year LCR varied from 27% to 62%, and the results from other reports fell in between those values. The 5-year OS rate ranged from 12% to 90%, and complete resection and tumor grade were the most important prognostic factors in most studies. This review resulted in 7 recommendations concerning the use of RT in the treatment of retroperitoneal sarcoma. The authors concluded that there is good evidence from multiple single-institutions studies that RT improves the LCR in patients with retroperitoneal sarcoma. Until now, there has not been a translation of this approach into survival benefit. The current results indicated that preoperative external-beam RT followed by radical surgery seems to be the preferred sequence, and adding intraoperative RT is a safe procedure for dose escalation in the upper abdomen. Cancer 2011;117:4355-

show abstract

Abdominal soft tissue sarcoma: a multicenter retrospective study

Abstract: Our results showed the clinical features and prognoses of retroperitoneal and abdominal STS in Japan. Further large-scale nationwide studies are required to clarify the detailed clinical behavior of retroperitoneal and abdominal STS in Japan.

Cited by 13 publications

References 17 publications

Primary mesenchymal tumors of the colon: A report of three cases

Primary mesenchymal tumors of the colon: A report of three cases

Outcomes of preoperative radiotherapy and resection of retroperitoneal sarcoma

Radiotherapy and surgery—An indispensable duo in the treatment of retroperitoneal sarcoma

Contact Info

Product

Resources

About